SignalFDA/Bio

MODERNA REPORTS FIRST POSITIVE PHASE 3 FOR MRNA NEOANTIGEN THERAPY IN MELANOMA - HN

First positive Phase 3 mRNA neoantigen data in melanoma.

What changed

Why it matters

First positive Phase 3 mRNA neoantigen data in melanoma.

Sources